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Genomewide Association Study of Statin-
Induced Myopathy in Patients Recruited Using 
the UK Clinical Practice Research Datalink
Daniel F. Carr1,*, Ben Francis2, Andrea L. Jorgensen2, Eunice Zhang1, Hector Chinoy3,4, Susan R. Heckbert5, 
Joshua C. Bis6,7, Jennifer A. Brody6,7, James S. Floyd6,7, Bruce M. Psaty6,7, Mariam Molokhia8,  
Maryse Lapeyre-Mestre9, Anita Conforti10, Ana Alfirevic1, Tjeerd van Staa11,12 and Munir Pirmohamed1
Statins can be associated with myopathy. We have undertaken a genomewide association study (GWAS) to 
discover and validate genetic risk factors for statin-induced myopathy in a “real-world” setting. One hundred thirty-
five patients with statin myopathy recruited via the UK Clinical Practice Research Datalink were genotyped using 
the Illumina OmniExpress Exome version 1.0 Bead Chip and compared with the Wellcome Trust Case-Control 
Consortium (n = 2,501). Nominally statistically significant single nucleotide polymorphism (SNP) signals in the GWAS 
(P < 5 × 10−5) were further evaluated in several independent cohorts (comprising 332 cases and 449 drug-tolerant 
controls). Only one (rs4149056/c.521C>T in the SLCO1B1 gene) SNP was genomewide significant in the severe 
myopathy (creatine kinase > 10 × upper limit of normal or rhabdomyolysis) group (P = 2.55 × 10−9; odds ratio 5.15; 
95% confidence interval 3.13–8.45). The association with SLCO1B1 was present for several statins and replicated in 
the independent validation cohorts. The data highlight the role of SLCO1B1 c.521C>T SNP as a replicable genetic risk 
factor for statin myopathy. No other novel genetic risk factors with a similar effect size were identified.
The  3-hydroxy-3-methyl-glutaryl-coenzyme A  inhibitors, or 
statins, are a widely prescribed class of drugs for the treatment 
of hyperlipidemia. Although generally well tolerated, a small 
proportion of patients can develop muscle-related adverse ef-
fects.1 These can range from mild muscle pain without creatine 
kinase (CK) elevation, where causality can be difficult to assess, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Risk of statin-induced myopathy is associated with varia-
tion of the SLCO1B1 gene, which encodes the OATP1B1 he-
patic uptake transporter, of which statins are substrates. To 
date, no other validated genetic risk factors have been identified.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Undertaking a genomewide association study in a “real-
world” patient cohort recruited via the Clinical Practice 
Research Datalink, this study aimed to determine whether 
any other novel genetic risk loci for statin myopathy could be 
identified.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 The study suggests that, aside from SLCO1B1, no other 
risk loci for statin myopathy are apparent. The unexplained sta-
tin myopathy risk is likely due to nongenetic risk factors or the 
influence of rare genetic variants analyzed in this study.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Common genetic variants do not seem to explain statin 
myopathy risk. The data presented seem to suggest that future 
translational work in this field should focus on rare variant 
analysis and on identifying nongenetic risk factors.
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to myopathy where the CK becomes elevated (>4 × upper limit of 
normal (ULN)), with the most extreme reactions being rhabdo-
myolysis with renal impairment.2 A systematic review suggested 
that the incidence of statin-induced mild muscle pain is 190 
cases/100,000 patient years with myopathy and rhabdomyolysis 
at 5 and 1.6 cases/100,000 patient years, respectively.3
A number of genetic studies4–8 have identified a nonsynon-
ymous polymorphism (p.V147L/c.521C>T) in the SLCO1B1 
gene (rs4149056), encoding a hepatic uptake transporter pro-
tein as a predisposing factor for statin myopathy. Our pilot 
proof-of-principle candidate gene study, which analyzed a sub-
set of the cohort in this study (77 cases and 372 statin-toler-
ant controls) replicated the association between the SLC01B1 
gene polymorphism and statin myopathy9 showing the valid-
ity of our recruitment strategy via the UK Clinical Practice 
Research Datalink (CPRD), an electronic health record data-
base. The association with the SLCO1B1 gene has biological 
plausibility in that it leads to impaired hepatic uptake of statins 
by the transporter,10,11 causing increased circulating drug con-
centrations.12,13 However, to date, no other clinically relevant, 
reproducible genetic variants have been identified.
Other genetic markers have been associated with statin-myop-
athy, including polymorphisms in the coenzyme Q2 4-hydroxy-
benzoate polyprenyltransferase (COQ2)14 and human eyes shut 
ortholog15 genes, but have not been independently replicated. The 
genetic association of statin myopathy with the GATM gene16 has 
also not been replicated.17,18
Utilizing patients with statin myopathy recruited via CPRD,19 
the aims of our study were twofold: to undertake a genomewide 
association study (GWAS) to identify novel genetic risk factors 
predisposing individuals to statin-induced myopathy, and to val-
idate any association in independent patient groups and perform 
 meta-analysis of any association signals. Taking all cohorts to-
gether, this represents the largest GWAS of the pharmacogenetics 
of statin myopathy undertaken to date.
RESULTS
Case-control discovery GWAS
A total of 128 of 135 myopathy case samples and 654,642 single 
nucleotide polymorphisms (SNPs) passed the predefined geno-
typing quality control (QC) criteria. Of the seven individuals 
excluded, three failed sample call-rate criteria, three failed the gen-
der identity check (due to sample mislabeling), and one individual 
was excluded as a population outlier after principal component 
analysis (Figure S1). The individual statins responsible for the 
muscle toxicity are shown in Table S1.
From the case-control discovery GWAS, a total of 21 SNPs were 
initially identified as notionally significant (P < 5 × 10−5; 12 from 
the all myopathy analysis and 9 from the severe myopathy analysis; 
Figure 1a,b, respectively). However, only one signal reached genome-
wide significance: rs4149056 in the SLCO1B1 locus (P = 2.5 × 10−9; 
Table 1). Sensitivity analysis of discovery cases (all myopathy) for sim-
vastatin cases only (Figure S3 and Table S4) showed no genomewide 
significant association signals (P  >  5  ×  10−8), although SLCO1B1 
was among the top associated loci. Similarly, sensitivity analysis of 
atorvastatin cases only (Figure S4 and Table S5) also showed no 
genomewide significant associations. SLCO1B1 was not identified in 
the top associated loci.
Univariate analysis of nongenetic variables for myopathy 
(n = 128) and severe myopathy (n = 32) cases vs. statin-tolerant 
controls (n = 585) was undertaken (Table S1). Age, gender, body 
mass index, antihypertensive comedication, occurrence of cramps, 
and history of hypertension showed an association with P < 0.10 
for all myopathy and mean daily dose, age, and occurrence of 
cramps showed an association with P < 0.10 for “severe myopathy.” 
These variables were incorporated into the replication cohort lo-
gistic regression model for case control analysis.
Replication cohort analysis
Twenty-one SNPs below a threshold of P < 5 × 10−5 in the dis-
covery GWAS analysis were carried forward for genotyping in the 
“Replication Cohort” (consisting of the CPRD statin-exposed 
controls (n  =  585) and the EUDRAGENE statin-myopathy 
cases (n = 19)). A total of 9 SNPs (two from the severe myopathy 
analysis and seven from the all myopathy analysis), however, were 
subsequently excluded because of inability to design TaqMan or 
MassArray assays due to proximal sequence constraints (n  =  4), 
low genotyping call rate (n = 4), and Hardy−Weinberg deviation 
(n = 1). Thus, a total of 12 SNPs were genotyped (5 for all myopa-
thy and 7 for severe myopathy; Table 1).
Data from simvastatin and atorvastatin cases only sensitivity 
analyses for the 12 SNPs initially identified in the overall discovery 
cohort is reported in Table S3. None of the 12 signals showed a sta-
tistically significant association with atorvastatin myopathy. Eight 
loci were notionally associated with simvastatin “all myopathy” al-
beit not to genomewide significance.
Replication cohort. Candidate gene analysis of the 19 EUDRAGENE 
myopathy cases (13 severe) with the 585 statin-tolerant controls 
identified 2 of 12 associations of nominal significance (P  <  0.05), 
both of which were for the severe myopathy phenotype (Table 1). 
These were SLCO1B1 rs4149056 (P = 0.001; odds ratio (OR) 3.98; 
95% confidence interval (CI) 1.75–9.03) and SLCO1A2 rs4149000 
(P  =  0.05; OR 2.53; 95% CI 1.00–6.39). No other statistically 
significant associations were observed in the other nine SNPs 
(P < 0.05). Minor allele frequencies for the 12 SNPs were comparable 
for both simvastatin and atorvastatin controls.
Association signal validation
“Simvastatin” cohort. Summary statistics from this cohort (Table 1) 
showed a genomewide significant association for 2 of 12 SNPs, both 
of which were associated with the severe myopathy phenotype in 
the initial analysis. Both rs4149056 in SLCO1B1 and rs4149000 
in SLCO1A2 were significantly associated with both definite 
myopathy (P = 7.30 × 10−14 and P = 7.62 × 10−11, respectively) and 
the incipient or definite myopathy phenotype (P = 1.33 × 10−11 and 
6.49 × 10−12). None of the other SNPs were significantly associated 
with either myopathy phenotype (P > 0.05).
“Cerivastatin” cohort. Summary statistics from the cerivastatin 
rhabdomyolysis validation cohort (Table 1) showed that the 
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same two SNPs (rs4149056 and rs4149000) showed a significant 
(albeit not to a genomewide threshold) association (3.90 × 10−4 
and 0.007, respectively). None of the other SNPs showed an 
association (P > 0.05).
Further analysis of the SLCO1B1 and SLCO1A2 signals
The two SNPs that seem to be strongly associated with statin 
myopathy in the discovery and replication cohorts are within 
two gene loci (SLCO1B1 and SLCO1A2) that are in a strong 
block of linkage disequilibrium in the discovery cohort (data 
not shown). Conditional analysis correcting for the SLCO1B1 
rs4149056 genotype was undertaken. The analysis of the 32 
discovery severe myopathy cases vs. 585 statin-tolerant controls 
abolished the rs4149000 genotype association (P  =  0.934), as 
well as for the all myopathy phenotype (P = 0.368) indicating 
that the two risk alleles are not acting in cis on the same hap-
lotype and that the SLCO1A2 association is not acting inde-
pendently of SLCO1B1.
Meta-analysis of SLCO1B1 and SLCO1A2 association signals
Meta-analysis combining the discovery and all replication cohorts 
(limited to severe cases only; 271 cases vs. 7,493 controls) yielded 
a meta-analytic genomewide significant P value for SLCO1B1, 
rs4149056 (P  =  2.63  ×  10−18; OR 2.99; 95% CI 2.34–3.82; 
Table 1), highlighting the predominant role of SLCO1B1 in 
predisposing to myopathy caused by a variety of statins. An 
Figure 1 Manhattan plot of genomewide association analysis of statin-induced myopathy. The data represents logistic regression derived 
log P values (y-axis) of single nucleotide polymorphisms (SNPs) for the discovery case-control analysis of (a) the “all myopathy” phenotype 
(n = 128) and (b) the “severe myopathy” sub-phenotype (n = 32) with the Wellcome Trust Case-Control Consortium 2 (WTCCC2) population 
controls (n = 2,501). X-axis is the position of the SNP with the chromosome indicated.
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increased statistical significance of the association signal within 
the SLCO1A2 was also observed, but no other meta-analysis 
demonstrated an increased statistical significance of the signal 
initially identified in the discovery case-control study (Table 1). 
Meta-analysis of the SLCO1B1 signal for rs4149056 limited to 
the simvastatin-exposed cases and controls only (Figure 2) led to 
a P value of 1.46 × 10−21 (OR 5.91; 95% CI 4.10–8.51; I2 = 1.00) 
for the severe myopathy phenotype and a P value of 2.01 × 10−14 
(OR 2.75; 95% CI 2.12–3.56; I2  =  0.78) for the all myopathy 
phenotype.
DISCUSSION
Our discovery GWAS identified 12 SNPs, which were nominally 
associated with either all myopathy (CK  >  4  ×  ULN  ±  muscle 
symptoms) or severe myopathy (CK > 10 × ULN or rhabdomy-
olysis). Replication was undertaken in three separate patient co-
horts, which showed that only the previously identified6,9 and 
widely replicated c.521C>T variant (rs4149056) in SLCO1B1 
and an intronic SNP in the SLCO1A2 gene were risk factors for 
statin myopathy. The latter, however, was not significant after ad-
justment for SLCO1B1 genotype. Our data concur with a previ-
ous statin myopathy GWAS,9 as well as our own pilot data9 and 
other candidate gene studies,4,5,8,20 that the SLCO1B1 c.521C>T 
polymorphism (rs4149056) is the predominant genetic risk factor 
for statin-induced myopathy. Our finding is also consistent with 
a recent meta-analysis of 14 studies comprising 3,265 myopathy 
patients and 7,743 controls.21 Additionally, previously reported 
associations in the GATM,16 COQ2,14 and human eyes shut or-
tholog15 gene loci were not replicated.
Our discovery cohort was heterogeneous in terms of the sever-
ity of myopathy and statin implicated. The association with the 
rs4149056 variant in SLCO1B1 was stronger in patients with the 
severe form of myopathy (CK > 10 × ULN or rhabdomyolysis) ir-
respective of the statin involved reaching genomewide significance 
(Figure 2). The lower effect size observed in patients with the less 
severe form of statin myopathy (defined in our discovery cohort as 
CK > 4 × ULN) may reflect multiple causes in the mildly affected 
cases and the difficulty in attributing causality to statins in all cases.
Of the different statins implicated, simvastatin was the most 
common, accounting for 66% of our cases and 69% of the severe 
cases. Meta-analysis of our discovery severe myopathy cohort with 
the simvastatin definite myopathy cohort did strengthen the as-
sociation (P = 7.17 × 10−19) with little evidence of heterogeneity 
between the two (I2 = 1). Further incorporation of the cerivastatin 
cohort marginally weakened the association in keeping with the dif-
ferent effect sizes of the SLCO1B1 locus for different statins. These 
data are consistent with the fact that the pharmacokinetic effect of 
the SLCO1B1 variant is greatest for simvastatin. The area under 
the curve for simvastatin acid is increased by 221% in CC homozy-
gotes compared with those individuals who are TT homozygotes 
for the SLCO1B1 c.521C>T polymorphism.13 Corresponding val-
ues for the other statins are as follows: atorvastatin (145%),22 flu-
vastatin (19%),23 lovastatin acid (186%),24 pitavastatin (208%),25 
pravastatin (91%),23 and rosuvastatin (65%).22 No similar data are 
available for cerivastatin. Based on these pharmacokinetic data and 
the results of our data, together with the recent meta-analysis,21 it 
might be suggested that SLCO1B1 locus is important for all statins, 
but the effect size will likely vary, being greatest for simvastatin and 
lowest for fluvastatin.
The aim of our GWAS was to identify other loci associated with 
statin myopathy. Apart from the association with SLCO1B1, we 
also identified an association with an SNP located in the 5′UTR 
of the SLCO1A2 locus (Figure S2). This signal, however, was 
not independent of the SLCO1B1 signal. SLCO1A2 encodes 
SLCO1A2, a hepatic-expressed efflux transporter,26 which is re-
sponsible for the sodium-independent transport of organic anions, 
such as bromosulfophthalein, taurocholate, and unconjugated 
cholate bile acids.27,28 SLCO1A2 has also been shown to have sub-
strate specificity for pitavastatin29 and rosuvastatin,30 but, to date, 
there is no evidence of its ability to transport simvastatin or ator-
vastatin. Determination of whether the SLCO1A2 locus can act as 
an independent risk factor for statin myopathy will require a much 
larger sample size. None of the other loci identified in the discov-
ery cohort were replicated in any of the cohorts, and meta-analysis 
did not provide any indication that these loci acted as predisposing 
factors for statin myopathy.
For a number of years, the c.521T>C SLCO1B1 variant has been 
recognized as a clinically important risk factor for statin-induced 
myopathy, particularly with regard to simvastatin, and to a lesser 
extent atorvastatin. Indeed, summary of product characteristics la-
beling for both drugs31,32 highlights the increased risk of myopathy 
in individuals who are carriers of the low-activity C allele. It has 
been suggested that the maximum dose of simvastatin, pitavastatin, 
and atorvastatin should be reduced by fourfold in individuals who 
are CC homozygotes based on pharmacokinetic calculations.33 
Interestingly, a recent small randomized trial (n = 159) of patients 
not on statins because of prior myalgia attributed to a statin showed 
that providing information on the SLCO1B1 genotype improved 
statin reinitiation and low-density lipoprotein-cholesterol lower-
ing, but not adherence, when compared with the usual care arm.34
It is clear that although SLCO1B1 is a key risk factor for statin 
myopathy, it does not explain a significant proportion of the inter-
individual variability in statin toxicity. Genetic studies to date have 
been limited by recruitment of significant numbers of cases of what 
is a rare adverse drug reaction. As such, many studies lack statistical 
power to detect small effect sizes and have, in fact, only identified 
the “low hanging fruit.” It is possible that much of the heritability of 
statin myopathy risk may lie either with rare variants of large effect 
sizes or with other common genetic loci with small to modest ef-
fect sizes, which will require much larger patient numbers. A major 
issue is that we do not fully understand the mechanism of statin 
myopathy and muscle damage, apart from the fact that high doses 
or high statin concentrations increase risk. Further functional stud-
ies to uncover the mechanisms of muscle damage induced by statins 
will be important in elucidating further predisposing factors.
In conclusion, our data further confirm the predominant role 
of the SLCO1B1 c.521 C>T polymorphism in predisposing to 
statin-induced myopathy in a “real-world” patient population, in 
particular with simvastatin. Moreover, the data failed to identify 
other statin myopathy-associated genetic risk factors. However, 
this meta-analysis is relatively small and may lack statistical power. 
The additional signal identified in the SLCO1A2 locus was not 
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independent of SLCO1B1, but may require further investigation 
from a functional perspective to determine the role of this trans-
porter in statin transport.
METHODS
The study design is summarized in Figure 3. Briefly, a discovery case-control 
GWAS was undertaken, followed by candidate variant replication in a sec-
ond case-control cohort. The same association signals were validated in ex-
isting data from two independent validation case-control studies.
CPRD case-control recruitment
From a cohort of ~ 600,000 patients receiving statins identified in the 
CPRD (www.cprd.com), a case-control design was used to identify suit-
able patients for the study, as previously described.19,35 Participation was 
restricted to white people ≥18 years of age and with the first ever statin 
prescription at least 1 year after the start of CPRD data collection.
All cases conformed to internationally agreed standards for statin-in-
duced myopathy and rhabdomyolysis.2 Cases were categorized into two 
groups: (i) myopathy: patients who discontinued their implicated statin 
with a rise in CK > 4 × ULN; and (ii) severe myopathy: individuals with 
a history of rhabdomyolysis or CK  >  10  ×  ULN after statin exposure. 
Controls were defined as individuals receiving statins for at least 3 months 
with no history of abnormal serum CK measurements.
General practitioners (GPs) were contacted with a list of potential cases 
and/or controls identified from their practice. They were first asked to re-
view the medical records of listed individuals and remove any patients they 
considered to not fulfill the case or control criteria. They were then asked 
to contact suitable patients by letter requesting participation. Individuals 
who gave written informed consent were invited to provide either a saliva 
sample (by post) or a blood sample (by visiting the practice). All samples 
were then forwarded on to the University of Liverpool for processing. 
To preserve anonymity, patient and practice identifier codes were used 
throughout the recruitment process and all patient contact was via the GP 
only. A total of 149 myopathy cases and 585 controls were recruited be-
tween April 2010 and June 2013, although only 135 cases were available 
at the time of genotyping.19 Relevant clinical and demographic data (sum-
marized in Table 1) was retrospectively obtained from the CPRD.
In addition to the above, five supplemental cases of statin-induced 
myopathy conforming to our phenotype criteria were identified in the 
tertiary adult muscle clinic run through Salford Royal NHS Foundation 
Trust, UK, and recruited into the UKMYONET genetic study.36
Additional cohorts and studies
Three replication cohorts were utilized to validate associations identified 
in the case-control discovery GWAS (summarized in Figure 3).
EUDRAGENE cohort. A total of 19 adults (>18 years of age) with statin-
exposed myopathy (5 simvastatin, 5 atorvastatin, 2 rosuvastatin, and 1 
fluvastatin) matching the case phenotype (defined above) were recruited 
using spontaneous adverse drug reaction reports and laboratory CK 
results from the European pharmacovigilance center and UK primary 
care practices from 2006−2012 via the EUDRAGENE collaborative 
network.37 All cases were adjudicated using internationally accepted 
criteria for myopathy and severe myopathy2 by an independent panel, 
consisting of clinicians and pharmacovigilance experts. Of the 19 cases, 
13 were categorized as having severe myopathy. EUDRAGENE cases 
were combined with the 585 CPRD statin-tolerant controls to form the 
“Replication cohort.”
The “simvastatin” validation case-control study. A total of 141 
patients with simvastatin myopathy were recruited via the SEARCH 
collaborative group.6 These consisted of 54 “definite” statin 
myopathies (defined as otherwise unexplained muscle symptoms with 
CK  >  10  ×  ULN) and 87 “incipient” statin myopathies (defined as 
alanine aminotransferase  >  1.7  ×  ULN and CK both >  5  ×  baseline 
and  >  3  ×  ULN). For the purpose of meta-analysis, the “definite” 
myopathy phenotype aligned to these studies was severe myopathy 
phenotype with both “incipient and definite” aligning to the all myopathy 
phenotype. A total of 4,046 statin-tolerant controls were included from 
the SEARCH and Heart Protection Study groups.6,38
The “cerivastatin” validation case-control study. The study sample 
consisted of data from 172 cases of cerivastatin rhabdomyolysis and 
361 statin-using controls from the Heart and Vascular Health study, as 
previously reported.7 All cases and controls were of European ancestry. 
Controls with creatine kinase levels > 10 × ULN were excluded.
Study approvals. Ethical approval for recruitment via CPRD was 
obtained from the National Research Ethics Committee North West 2 
– Liverpool Central. Furthermore, approval to use the CPRD data was 
obtained from the Independent Scientific Advisory Committee at the 
Medicines and Healthcare products Regulatory Agency. In addition, 
site-specific approval to contact the GP practices was obtained for each 
of 132 primary care trusts across the United Kingdom, as described 
previously.39 Written informed consent was obtained from all study 
subjects or their guardians. The UKMYONET study was approved by 
the North West Research Multi-Centre Research Ethics Committee 
(98/8/86), and all participants gave written informed consent.
Multicenter ethics approval was obtained from the South East Research 
Ethics Committee for the SEARCH study and from the local ethics 
committees covering each of the 69 UK hospitals involved in the Heart 
Protection Study.
Figure 2 Forest plot depicting meta-analysis for the SLCO1B1 c.521T>C (rs4149056) polymorphism for both “all myopathy” (creatine kinase 
(CK) > 4 × upper limit of normal (ULN)) and “severe myopathy” (CK > 10 × ULN/rhabdomyolysis) phenotypes caused by all statins (upper 
panels) and simvastatin only (lower panels).  CI, confidence interval; OR, odds ratio;  WTCCC, Wellcome Trust Case-Control Consortium.
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The recruitment of cerivastatin case subjects was approved by the 
University of Washington Institutional Review Board, and the use of the 
Heart and Vascular Health study subjects was approved by the Group 
Health Subjects Review Committee.
DNA extraction and genotyping
Case-control “discovery” cohort. For the CPRD recruits (cases and 
controls), genomic DNA was extracted from 5 mL whole blood or 2 mL 
saliva (collected using the Oragene DNA Sampling kit; DNAGenotek, 
Ontario, Canada) using the Chemagic Magnetic Module (MSM) 1 
system, as per the manufacturer’s protocol (Chemagen Biopolymer-
Technologie AG, Baesweiler, Germany).
At the time of analysis, DNA samples from a total of 135 myopathy 
cases from the discovery cohort were available. At least 1.5 μg DNA from 
myopathy cases was genotyped for a total of 982,958 SNPs by ARK-
Genomics, University of Edinburgh (Edinburgh, UK) using the Illumina 
OmniExpress Exome version 1.0 Bead Chip array according to the manu-
facturers protocol (Illumina, San Diego, CA).
Discovery case-control study-population controls. Population control 
genotype data for the initial discovery case-control GWAS was obtained 
from the Wellcome Trust Case-Control Consortium 2 (WTCCC2) 
cohort of 2,501 individuals from the UK Blood Service.
Replication study. All 585 CPRD statin-tolerant controls and 
19 patients with myopathy from the EUDRAGENE cohort were 
genotyped for statistically significant association signals identified in 
the case-control discovery GWAS (P < 5 × 10−5) using either the Agena 
MassArray iPLEX platform (Agena Biosciences, San Diego, CA) or 
TaqMan real-time polymerase chain reaction SNP genotyping assay (Life 
Technologies, Paisley, UK), according to the manufacturer’s protocols.
Genotyping QC and imputation
Case-control “discovery” cohort. Cases identified via CPRD 
recruitment were excluded if they failed to meet the following criteria: 
(i) gender as determined by the “Sex Check” function within PLINK40 
differed from that reported in the clinical data; (ii) genotype call-rate 
< 90%; and (iii) principle component analysis (using SNPRelate41 in R 
version 3.01) demonstrated that the individual did not cluster with the 
HapMap CEU (Utah residents with European ancestry) population 
(Figure S1).
SNPs, in both the discovery and replication cohorts, were excluded if 
(i) minor allele frequency was < 0.01, (ii) Hardy–Weinberg Equilibrium 
P value was < 0.0001, and (iii) the genotype success rate was < 95%. All 
QC analysis was undertaken using PLINK version 1.0740 unless otherwise 
stated.
For the purpose of the discovery case-control study, the CPRD case 
genotype dataset was merged with the WTCCC dataset prior to SNP 
phasing using SHAPEIT42 and imputation using IMPUTE243,44 was un-
dertaken using the 1000 Genomes Project phase III reference panel.
The “simvastatin” validation case-control study. Genotype 
imputation was undertaken using minimac45 with the 1000 Genomes 
European reference panel. Data for the association signal SNPs were 
provided for the validation and meta-analysis.
The “cerivastatin” validation case-control study. Samples 
were excluded from analysis for gender mismatch or call rate 
<  95%. The following variant exclusions were applied to obtain 
a cleaned set of variants for imputation: call rate <  97%, Hardy–
Weinberg Equilibrium P < 10−5, >2 duplicate errors or Mendelian 
inconsistencies (for reference Centre d’Etude du Polymophisme 
Humain (CEPH) trios), heterozygote frequency  =  0. MaCH45 
was used to pre-phase the genotypes. The phased genotypes were 
imputed into a reference panel of 1,092 individuals of multiple 
ethnicities from the phase I (version 3) haplotypes of 1000 Genomes 
Project using minimac.45 Genotyping and SNP calling were 
performed using the Illumina 370CNV Bead Chip, as previously 
described.7 Data for the association signal SNPs were provided for 
the validation and meta-analysis.
Statistical analysis
The study design and statistical analysis are summarized in Figure 3. In 
the discovery phase, cases passing genotype QC (n = 128) recruited via 
CPRD were compared with WTCCC2 controls (n = 2,501) using a lo-
gistic regression analysis undertaken in SNPTest46 and adjusting for the 
Figure 3 Schematic representation of the discovery, replication, and validation cohort case-control analyses and subsequent meta-analysis 
performed. Patient numbers represent those included in analyses post-sample quality control. CPRD, Clinical Practice Research Datalink; 
GWAS, genomewide association study; SNP, single nucleotide polymorphism; WTCCC, Wellcome Trust Case-Control Consortium 2.
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first two principle components as covariates. All SNPs giving a P value 
for association of < 5 × 10−5 were genotyped in the statin-tolerant cohort 
(n = 585) and EUDRAGENE cohort (n = 19), which together formed 
the replication cohort.
A univariate analysis of nongenetic covariates (χ2 for categorical out-
comes and Student’s t-test for continuous variables) was undertaken 
(Table 1) using SPSS version 17.0. Variables demonstrating a P value 
<  0.10 between the discovery cohort cases and tolerant controls were 
carried forward and adjusted for in the SNP association analyses (Table 
S1). Logistic regression analysis of the candidate SNPs in the cases (dis-
covery and replication) and statin-tolerant controls was undertaken using 
SNPTest. Meta-analysis of the combined discovery and replication cohorts 
along with the two validation studies was undertaken using a fixed-effects 
model with inverse-variant effect size weighting in GWAMA.47 Forest 
plots were prepared using the “forestplot” function in R.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Supplementary Material: Tables and Figures.
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